Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VRAX by emailGet an email when VRAX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VRAX, unsubscribe in one click. Privacy
📣 What VRAX Says Is Next
Q4 2026 · “Virax is preparing for its next major development milestone: a larger clinical validation analysis involving previously collected samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027.”
Company press release, May 26, 2026 · SEC filing
first half of 2028 · “Virax intends to use the net proceeds from the offering for general working capital needs, expecting to extend the Company’s cash runway into the first half of 2028, which is beyond planned completion of the US based post-acute sequelae of COVID-19 (“PASC”, or long COVID) study for submission to the FDA, as well as completion of the UK studies in post-acute infection syndrome (PAIS) for submission to the MHRA.”
Company press release, Dec 4, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full VRAX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VRAX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.